Amylyx Pharmaceuticals, Inc.

NasdaqGS AMLX

Amylyx Pharmaceuticals, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024

Amylyx Pharmaceuticals, Inc. Operating Income is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Amylyx Pharmaceuticals, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -7.72 M, a 95.83% change year over year.
Amylyx Pharmaceuticals, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -185.06 M, a -193.91% change year over year.
Amylyx Pharmaceuticals, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -62.97 M.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGS: AMLX

Amylyx Pharmaceuticals, Inc.

CEO	Mr. Joshua B. Cohen
IPO Date	Jan. 7, 2022
Location	United States
Headquarters	43 Thorndike Street
Employees	384
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years